The effects of doxycycline on reducing symptoms in knee osteoarthritis: results from a triple-blinded randomised controlled trial
- PMID: 21551510
- DOI: 10.1136/ard.2010.147967
The effects of doxycycline on reducing symptoms in knee osteoarthritis: results from a triple-blinded randomised controlled trial
Abstract
Objectives: Evidence suggests that doxycycline might have disease-modifying properties in osteoarthritis. However, the clinically relevant question as to whether doxycycline also modifies symptoms in knee osteoarthritis is unanswered. The objective of this study was to investigate the effectiveness of doxycycline on pain and daily functioning in symptomatic knee osteoarthritis.
Methods: A 24-week, randomised, triple-blind, placebo controlled trial on the symptomatic effectiveness of doxycycline twice a day 100 mg in knee osteoarthritis patients according to the clinical and radiological American College of Rheumatology classification criteria. The primary endpoint was the difference in the proportion of participants in both study groups achieving a clinical response defined by the OMERACT-OARSI set of responder criteria. Secondary endpoints included pain, stiffness, daily functioning, patient global assessment, quality of life, osteoarthritis-related medication and side effects.
Results: 232 patients were randomly assigned. At study end, 31% of participants met the primary endpoint in both groups. Except for more adverse events in the doxycycline group, no differences were also found on the secondary endpoints.
Conclusions: Doxycycline is not effective in reducing symptoms in knee osteoarthritis patients over a 24-week study period, but is associated with an increased risk of adverse events. Although a possible structure-modifying effect of doxycycline was previously suggested, this is not accompanied by symptom relief in the short and medium term. Dutch Trial Register no NTR1111.
Comment in
-
Why should we expect a structure-modifying osteoarthritis drug to relieve osteoarthritis pain?Ann Rheum Dis. 2011 Jul;70(7):1175-7. doi: 10.1136/ard.2011.150953. Ann Rheum Dis. 2011. PMID: 21622770 No abstract available.
Similar articles
-
Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial.Osteoarthritis Cartilage. 2018 May;26(5):631-640. doi: 10.1016/j.joca.2018.01.026. Epub 2018 Feb 7. Osteoarthritis Cartilage. 2018. PMID: 29426008 Clinical Trial.
-
Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study.Ann Rheum Dis. 2007 May;66(5):639-45. doi: 10.1136/ard.2006.059899. Epub 2007 Jan 4. Ann Rheum Dis. 2007. PMID: 17204566 Free PMC article. Clinical Trial.
-
Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Arthritis Rheumatol. 2017 Jan;69(1):77-85. doi: 10.1002/art.39819. Arthritis Rheumatol. 2017. PMID: 27477804 Clinical Trial.
-
Tramadol for osteoarthritis.Cochrane Database Syst Rev. 2019 May 27;5(5):CD005522. doi: 10.1002/14651858.CD005522.pub3. Cochrane Database Syst Rev. 2019. PMID: 31132298 Free PMC article.
-
Oral or transdermal opioids for osteoarthritis of the knee or hip.Cochrane Database Syst Rev. 2014 Sep 17;2014(9):CD003115. doi: 10.1002/14651858.CD003115.pub4. Cochrane Database Syst Rev. 2014. PMID: 25229835 Free PMC article.
Cited by
-
State-of-the-Art management of knee osteoarthritis.World J Clin Cases. 2015 Feb 16;3(2):89-101. doi: 10.12998/wjcc.v3.i2.89. World J Clin Cases. 2015. PMID: 25685755 Free PMC article. Review.
-
The Current Role of Disease-modifying Osteoarthritis Drugs.Arch Bone Jt Surg. 2023;11(1):11-22. doi: 10.22038/ABJS.2021.56530.2807. Arch Bone Jt Surg. 2023. PMID: 36793668 Free PMC article. Review.
-
Chondroprotective Factors in Osteoarthritis: a Joint Affair.Curr Rheumatol Rep. 2019 Jun 21;21(8):41. doi: 10.1007/s11926-019-0840-y. Curr Rheumatol Rep. 2019. PMID: 31227927 Free PMC article. Review.
-
Immunotherapy of Autoimmune Diseases with Nonantibiotic Properties of Tetracyclines.Immune Netw. 2020 Dec 21;20(6):e47. doi: 10.4110/in.2020.20.e47. eCollection 2020 Dec. Immune Netw. 2020. PMID: 33425432 Free PMC article. Review.
-
MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial.Trials. 2022 Jan 31;23(1):98. doi: 10.1186/s13063-021-05982-3. Trials. 2022. PMID: 35101085 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous